GlassScriptPhysician profile
Randy D Bain
NPI 1013321892
$379.24
in general payments reported to CMS, 2019-2025
16 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $75.30 · 2023: $57.65 · 2024: $45.44 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.80 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $42.59 | 2022 | |
| Abbvie INC. | $32.97 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $32.71 | 2022 | |
| Dexcom, INC. | $29.16 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $28.78 | 2023-2025 | Evenity, Prolia |
| Novo Nordisk INC | $27.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $23.57 | 2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $16.38 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.61 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $15.22 | 2025 | Rexulti |
| Viatris Specialty LLC | $14.39 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $14.21 | 2025 | Nexletol |
| Lilly USA, LLC | $14.14 | 2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $13.78 | 2024 | Airsupra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $13.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.